DDrare: Database of Drug Development for Rare Diseases

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACE I, ATA II and Statins; ACE-inhibitor; AT1-inhibitor; Atrasentan; BARDOXOLONE METHYL; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Benazepril; Benazepril, Valsartan and Fluvastatin; Delix; Fluvastatin; Gold; HMG-Coenzyme inhibitor (statin); Hydroxychloroquine; Lademirsen (SAR339375); Paricalcitol; RAMIPRIL; RG-012; RG012; RTA 402; Ramipril; Spironolactone; Valsartan

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004395-22-FR (EUCTR)	04/12/2017	05/12/2017	clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndrome	A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL	Alport Syndrome MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Bardoxolone Methyl Product Code: RTA 402 INN or Proposed INN: bardoxolone methyl Other descriptive name: BARDOXOLONE METHYL	Reata Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2;Phase 3	United States;France;Canada;Spain;Australia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-004395-22-FR
(EUCTR)

04/12/2017

05/12/2017

clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndrome

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL

Alport Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Product Name: Bardoxolone Methyl
Product Code: RTA 402
INN or Proposed INN: bardoxolone methyl
Other descriptive name: BARDOXOLONE METHYL

Reata Pharmaceuticals, Inc.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

150

Phase 2;Phase 3

United States;France;Canada;Spain;Australia;Germany;United Kingdom